Literature DB >> 1908755

An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

S M Erdman1, K A Rodvold, R D Pryka.   

Abstract

Aminoglycoside antibiotics continue to be useful for the treatment of Gram-negative infections. Available dosing methods include predictive algorithms and nomograms, pharmacokinetics-based dosing methods, and methods that incorporate Bayesian forecasting. The individualised Sawchuk-Zaske and Bayesian methods have been extensively evaluated since the previous review in the Journal. Both methods continue to be rapid and accurate means of individualising dosage requirements for patients with diverse pharmacokinetic profiles. The predictive performance of the Bayesian method can be further enhanced when population-based parameters reflect the patient population being monitored. There are now several cost-effectiveness studies that demonstrate that pharmacokinetic dosing services for aminoglycosides result in cost savings, better therapeutic concentrations, fewer toxic serum concentrations, and shorter mean durations of hospital stay and aminoglycoside therapy. Further studies are needed for cost-effectiveness and comparison of various dosing methods in paediatric and neonatal patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908755     DOI: 10.2165/00003088-199120050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  76 in total

1.  Aminoglycoside dosing in pediatric patients.

Authors:  B C Carlstedt; M Uaamnuichai; R B Day; L Bowman; D C Brater
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

2.  A Bayesian feedback method of aminoglycoside dosing.

Authors:  M E Burton; D C Brater; P S Chen; R B Day; P J Huber; M R Vasko
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

3.  Cost/benefit analysis of aminoglycoside use without a kinetic dosing service.

Authors:  G R Bailie; A Mathews
Journal:  Drug Intell Clin Pharm       Date:  1988-01

4.  Multiple-dose nonlinear regression analysis program for the microcomputer.

Authors:  J R Koup; J Horn
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

5.  Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis.

Authors:  C J Destache; S K Meyer; K M Rowley
Journal:  Ther Drug Monit       Date:  1990-09       Impact factor: 3.681

6.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

7.  Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization.

Authors:  K D Crist; M C Nahata; J Ety
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

8.  A model for predicting nephrotoxicity in patients treated with aminoglycosides.

Authors:  C L Sawyers; R D Moore; S A Lerner; C R Smith
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

9.  Antimicrobial agents in patients with renal insufficiency.

Authors:  R E Van Scoy; W R Wilson
Journal:  Mayo Clin Proc       Date:  1983-04       Impact factor: 7.616

10.  A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients.

Authors:  K Hickling; E Begg; M L Moore
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

View more
  11 in total

1.  Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.

Authors:  J Debord; J C Voultoury; G Lachatre; C Gay; J P Favereau; R Gay
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

3.  Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study.

Authors:  Robert E Ariano; Daniel S Sitar; Maria Davi; Sheryl A Zelenitsky
Journal:  Curr Ther Res Clin Exp       Date:  2003-03

4.  Estimation of pharmacokinetic parameters based on the patient-adjusted population data.

Authors:  Reza Mehvar
Journal:  Am J Pharm Educ       Date:  2006-10-15       Impact factor: 2.047

Review 5.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 6.  Bayesian forecasting in paediatric populations.

Authors:  M M Fernández de Gatta; M J García; J M Lanao; A Domínguez-Gil
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

7.  Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients.

Authors:  A Abdel-Bari; M Sherif Mokhtar; Nagwa Ali Sabry; Sanaa Abd El-Shafi; Naglaa Samir Bazan
Journal:  Saudi Pharm J       Date:  2010-11-04       Impact factor: 4.330

Review 8.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 9.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

10.  Amikacin population pharmacokinetics in critically ill Kuwaiti patients.

Authors:  Kamal M Matar; Yousef Al-lanqawi; Kefaya Abdul-Malek; Roger Jelliffe
Journal:  Biomed Res Int       Date:  2013-01-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.